These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24989624)

  • 1. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.
    Canet MJ; Cherrington NJ
    Expert Opin Drug Metab Toxicol; 2014 Sep; 10(9):1209-19. PubMed ID: 24989624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug disposition in cholestasis: An important concern.
    Shang T; Zhang C; Liu D
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1220. PubMed ID: 38899589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Liver Disease on Hepatic Transporter Expression and Function.
    Thakkar N; Slizgi JR; Brouwer KLR
    J Pharm Sci; 2017 Sep; 106(9):2282-2294. PubMed ID: 28465155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of drug-metabolizing enzymes by local and systemic liver injuries.
    Guo Y; Hu B; Xie Y; Billiar TR; Sperry JL; Huang M; Xie W
    Expert Opin Drug Metab Toxicol; 2016; 12(3):245-51. PubMed ID: 26751558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of drug transporter pharmacogenetics on cholestasis.
    Dietrich CG; Geier A
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1533-51. PubMed ID: 25260651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.
    Laddha AP; Dzielak L; Lewis C; Xue R; Manautou JE
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167037. PubMed ID: 38295624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Transporters in Xenobiotic Disposition and Pharmacokinetic Prediction.
    Mao Q; Lai Y; Wang J
    Drug Metab Dispos; 2018 May; 46(5):561-566. PubMed ID: 29636376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of ABC and SLC transporters in the pharmacokinetics of dietary and herbal phytochemicals and their interactions with xenobiotics.
    Li Y; Lu J; Paxton JW
    Curr Drug Metab; 2012 Jun; 13(5):624-39. PubMed ID: 22475331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.
    Dietrich CG; Rau M; Jahn D; Geier A
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):625-640. PubMed ID: 28359183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug transporters in pharmacokinetics.
    Petzinger E; Geyer J
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Mar; 372(6):465-75. PubMed ID: 16532306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transporters and their impact on drug disposition.
    Beringer PM; Slaughter RL
    Ann Pharmacother; 2005 Jun; 39(6):1097-108. PubMed ID: 15886292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions.
    Somabattini RA; Sherin S; Siva B; Chowdhury N; Nanjappan SK
    Life Sci; 2024 Aug; 351():122806. PubMed ID: 38852799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.
    Clarke JD; Cherrington NJ
    Pharmacol Ther; 2015 Jul; 151():99-106. PubMed ID: 25805597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug disposition in pathophysiological conditions.
    Gandhi A; Moorthy B; Ghose R
    Curr Drug Metab; 2012 Nov; 13(9):1327-44. PubMed ID: 22746301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of transporters in toxicity and disease.
    Schuetz JD; Swaan PW; Tweedie DJ
    Drug Metab Dispos; 2014 Apr; 42(4):541-5. PubMed ID: 24598705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal transporters in drug development.
    Morrissey KM; Stocker SL; Wittwer MB; Xu L; Giacomini KM
    Annu Rev Pharmacol Toxicol; 2013; 53():503-29. PubMed ID: 23140242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species.
    van Groen BD; Nicolaï J; Kuik AC; Van Cruchten S; van Peer E; Smits A; Schmidt S; de Wildt SN; Allegaert K; De Schaepdrijver L; Annaert P; Badée J
    Pharmacol Rev; 2021 Apr; 73(2):597-678. PubMed ID: 33608409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
    Clarke JD; Cherrington NJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):349-60. PubMed ID: 22280100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics.
    Foti RS; Dalvie DK
    Drug Metab Dispos; 2016 Aug; 44(8):1229-45. PubMed ID: 27298339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does hepatic steatosis affect drug metabolizing enzymes in the liver?
    Buechler C; Weiss TS
    Curr Drug Metab; 2011 Jan; 12(1):24-34. PubMed ID: 21222589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.